Free Trial

Connect Biopharma (CNTB) Competitors

Connect Biopharma logo
$1.72 -0.14 (-7.53%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 -0.03 (-2.03%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNTB vs. NGNE, CADL, TNXP, IVA, PVLA, LFCR, ABEO, ALDX, CRVS, and DBVT

Should you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Neurogene (NGNE), Candel Therapeutics (CADL), Tonix Pharmaceuticals (TNXP), Inventiva (IVA), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), Corvus Pharmaceuticals (CRVS), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

Connect Biopharma vs. Its Competitors

Neurogene (NASDAQ:NGNE) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Connect Biopharma has higher revenue and earnings than Neurogene.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurogene$930K342.55-$75.14M-$4.35-5.14
Connect Biopharma$26.03M3.67-$15.63MN/AN/A

Neurogene currently has a consensus target price of $46.17, indicating a potential upside of 106.65%. Connect Biopharma has a consensus target price of $7.00, indicating a potential upside of 306.98%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurogene
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Connect Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Connect Biopharma's return on equity of 0.00% beat Neurogene's return on equity.

Company Net Margins Return on Equity Return on Assets
NeurogeneN/A -36.16% -32.51%
Connect Biopharma N/A N/A N/A

In the previous week, Connect Biopharma had 5 more articles in the media than Neurogene. MarketBeat recorded 5 mentions for Connect Biopharma and 0 mentions for Neurogene. Neurogene's average media sentiment score of 1.89 beat Connect Biopharma's score of 0.43 indicating that Neurogene is being referred to more favorably in the media.

Company Overall Sentiment
Neurogene Very Positive
Connect Biopharma Neutral

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 11.6% of Neurogene shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neurogene has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, meaning that its share price is 120% less volatile than the S&P 500.

Summary

Connect Biopharma beats Neurogene on 9 of the 13 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CNTB vs. The Competition

MetricConnect BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$103.34M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E RatioN/A8.2821.0120.09
Price / Sales3.67303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book1.037.678.125.65
Net Income-$15.63M-$55.28M$3.25B$257.91M
7 Day Performance13.16%2.50%0.97%2.09%
1 Month Performance71.98%11.70%7.36%11.13%
1 Year Performance34.38%4.89%31.31%18.40%

Connect Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTB
Connect Biopharma
2.6238 of 5 stars
$1.72
-7.5%
$7.00
+307.0%
+44.2%$103.34M$26.03M0.00110News Coverage
High Trading Volume
NGNE
Neurogene
3.445 of 5 stars
$22.38
+4.4%
$46.17
+106.3%
-49.0%$319.11M$925K-5.1490
CADL
Candel Therapeutics
2.518 of 5 stars
$6.37
+9.6%
$22.00
+245.5%
+5.3%$319.06MN/A-4.7560Positive News
TNXP
Tonix Pharmaceuticals
2.6032 of 5 stars
$42.75
+4.6%
$585.00
+1,268.3%
-20.8%$314.54M$10.04M-0.0250Gap Up
IVA
Inventiva
3.0874 of 5 stars
$3.21
-4.3%
$10.40
+224.5%
+30.6%$306.59M$9.95M0.00100
PVLA
Palvella Therapeutics
2.9642 of 5 stars
$27.42
+3.6%
$46.29
+68.8%
N/A$303.16MN/A-2.27N/APositive News
LFCR
Lifecore Biomedical
1.0039 of 5 stars
$8.17
-1.6%
$8.00
-2.0%
+38.1%$302.86M$130.31M-5.64690News Coverage
ABEO
Abeona Therapeutics
3.8465 of 5 stars
$5.90
+2.8%
$19.25
+226.3%
+22.3%$301.79M$3.50M-4.6490
ALDX
Aldeyra Therapeutics
2.399 of 5 stars
$5.01
+7.8%
$9.50
+89.5%
+23.6%$296.79MN/A-5.1110News Coverage
Positive News
CRVS
Corvus Pharmaceuticals
2.8841 of 5 stars
$4.32
+4.4%
$15.00
+247.1%
+95.9%$294.63MN/A-4.4130Positive News
DBVT
DBV Technologies
4.0198 of 5 stars
$10.73
-0.7%
$14.75
+37.5%
+142.8%$293.76M$4.15M-2.1880Positive News

Related Companies and Tools


This page (NASDAQ:CNTB) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners